노인황반변성 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 질환 단계별, 치료법별, 판매 채널별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Macular Degeneration Treatment Market will grow from USD 14.19 Billion in 2024 to USD 22.90 Billion by 2030 at a 8.30% CAGR. Macular degeneration treatments encompass a range of pharmacological interventions, primarily anti-vascular endothelial growth factor (anti-VEGF) agents, along with other supportive therapies designed to manage age-related macular degeneration (AMD), a progressive ophthalmic condition leading to central vision loss.

Key Market Drivers

The global macular degeneration treatment market is significantly propelled by the increasing worldwide prevalence of age-related macular degeneration and continuous advancements in therapeutic modalities and drug development. The rising incidence of AMD creates an expanding patient pool demanding effective interventions. For instance, according to Eye Health Central, in 2025, approximately 200 million people worldwide are living with some form of age-related macular degeneration, underscoring the vast and growing clinical need that drives market demand.

Key Market Challenges

The substantial economic burden associated with long-term treatment regimens, particularly the recurring intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents, directly hampers the growth of the global macular degeneration treatment market. This financial strain presents a significant barrier, limiting patient access to necessary therapies and placing considerable pressure on healthcare budgets across various regions. The chronic nature of age-related macular degeneration (AMD) necessitates ongoing treatment, often involving frequent injections, which accumulates substantial costs over time for individuals and health systems.

Key Market Trends

The development of complement system inhibitors for dry age-related macular degeneration (AMD) represents a significant growth trend, addressing a substantial unmet medical need. Geographic atrophy, an advanced form of dry AMD, previously lacked approved disease-modifying therapies. These novel inhibitors target specific components of the complement cascade, an immune pathway implicated in dry AMD's pathogenesis and progression. Such targeted treatments offer the potential to slow disease progression and preserve vision.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc

Report Scope:

In this report, the Global Macular Degeneration Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Macular Degeneration Treatment Market, By Type:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Macular Degeneration Treatment Market, By Stage of Disease:

• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Macular Degeneration Treatment Market, By Treatment Type:

• Drug
• Devices
• Surgery

Macular Degeneration Treatment Market, By Sales Channel:

• Ambulatory Surgical Centers
• Hospitals
• Other

Macular Degeneration Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Macular Degeneration Treatment Market.

Available Customizations:

Global Macular Degeneration Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Macular Degeneration Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
  • 5.2.2. By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
  • 5.2.3. By Treatment Type (Drug, Devices, Surgery)
  • 5.2.4. By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Macular Degeneration Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Stage of Disease
  • 6.2.3. By Treatment Type
  • 6.2.4. By Sales Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Macular Degeneration Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Stage of Disease
      • 6.3.1.2.3. By Treatment Type
      • 6.3.1.2.4. By Sales Channel
  • 6.3.2. Canada Macular Degeneration Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Stage of Disease
      • 6.3.2.2.3. By Treatment Type
      • 6.3.2.2.4. By Sales Channel
  • 6.3.3. Mexico Macular Degeneration Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Stage of Disease
      • 6.3.3.2.3. By Treatment Type
      • 6.3.3.2.4. By Sales Channel

7. Europe Macular Degeneration Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Stage of Disease
  • 7.2.3. By Treatment Type
  • 7.2.4. By Sales Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Macular Degeneration Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Stage of Disease
      • 7.3.1.2.3. By Treatment Type
      • 7.3.1.2.4. By Sales Channel
  • 7.3.2. France Macular Degeneration Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Stage of Disease
      • 7.3.2.2.3. By Treatment Type
      • 7.3.2.2.4. By Sales Channel
  • 7.3.3. United Kingdom Macular Degeneration Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Stage of Disease
      • 7.3.3.2.3. By Treatment Type
      • 7.3.3.2.4. By Sales Channel
  • 7.3.4. Italy Macular Degeneration Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Stage of Disease
      • 7.3.4.2.3. By Treatment Type
      • 7.3.4.2.4. By Sales Channel
  • 7.3.5. Spain Macular Degeneration Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Stage of Disease
      • 7.3.5.2.3. By Treatment Type
      • 7.3.5.2.4. By Sales Channel

8. Asia Pacific Macular Degeneration Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Stage of Disease
  • 8.2.3. By Treatment Type
  • 8.2.4. By Sales Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Macular Degeneration Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Stage of Disease
      • 8.3.1.2.3. By Treatment Type
      • 8.3.1.2.4. By Sales Channel
  • 8.3.2. India Macular Degeneration Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Stage of Disease
      • 8.3.2.2.3. By Treatment Type
      • 8.3.2.2.4. By Sales Channel
  • 8.3.3. Japan Macular Degeneration Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Stage of Disease
      • 8.3.3.2.3. By Treatment Type
      • 8.3.3.2.4. By Sales Channel
  • 8.3.4. South Korea Macular Degeneration Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Stage of Disease
      • 8.3.4.2.3. By Treatment Type
      • 8.3.4.2.4. By Sales Channel
  • 8.3.5. Australia Macular Degeneration Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Stage of Disease
      • 8.3.5.2.3. By Treatment Type
      • 8.3.5.2.4. By Sales Channel

9. Middle East & Africa Macular Degeneration Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Stage of Disease
  • 9.2.3. By Treatment Type
  • 9.2.4. By Sales Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Macular Degeneration Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Stage of Disease
      • 9.3.1.2.3. By Treatment Type
      • 9.3.1.2.4. By Sales Channel
  • 9.3.2. UAE Macular Degeneration Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Stage of Disease
      • 9.3.2.2.3. By Treatment Type
      • 9.3.2.2.4. By Sales Channel
  • 9.3.3. South Africa Macular Degeneration Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Stage of Disease
      • 9.3.3.2.3. By Treatment Type
      • 9.3.3.2.4. By Sales Channel

10. South America Macular Degeneration Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Stage of Disease
  • 10.2.3. By Treatment Type
  • 10.2.4. By Sales Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Macular Degeneration Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Stage of Disease
      • 10.3.1.2.3. By Treatment Type
      • 10.3.1.2.4. By Sales Channel
  • 10.3.2. Colombia Macular Degeneration Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Stage of Disease
      • 10.3.2.2.3. By Treatment Type
      • 10.3.2.2.4. By Sales Channel
  • 10.3.3. Argentina Macular Degeneration Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Stage of Disease
      • 10.3.3.2.3. By Treatment Type
      • 10.3.3.2.4. By Sales Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Macular Degeneration Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Pfizer Inc.
• 15.4. PanOptica Inc.
• 15.5. Bausch Health Companies Inc.
• 15.6. Regeneron Pharmaceuticals Inc.
• 15.7. Aerie Pharmaceutical Inc.
• 15.8. REGENXBIO Inc.
• 15.9. Bayer AG
• 15.10. Lineage Cell Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer